Tan et al. (2014) showed that every cancer has an unique cancer-specific EMT signature and EMT spectrums varied between different cell lines and tumors. EpCAM and CSV can be used as targets to isolate the epithelial and mesenchymal subtypes of CTCs, respectively. Studies in breast and pancreatic cancers have shown the use of CSV is more efficient to capture CTCs than EpCAM (Satelli et al., 2015; Wei et al., 2019). This evidence concerns the gene EPCAM and cancer.